Avandia ethical concerns could spur changes in US head-to-head safety studies
This article was originally published in SRA
Executive Summary
Ethical concerns about GlaxoSmithKline’s ongoing study comparing the safety of its diabetes agent Avandia (rosiglitazone) with that of Takeda’s competing glitazone Actos (pioglitazone) could lead to changes in how such head-to-head safety trials are approved and conducted in the US.